company background image
5326

Nectar Lifesciences BSE:532649 Stock Report

Last Price

₹22.80

Market Cap

₹5.1b

7D

-3.8%

1Y

-23.0%

Updated

25 Sep, 2022

Data

Company Financials
532649 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends0/6

532649 Stock Overview

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally.

Nectar Lifesciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nectar Lifesciences
Historical stock prices
Current Share Price₹22.80
52 Week High₹38.95
52 Week Low₹20.75
Beta0.76
1 Month Change-0.65%
3 Month Change-1.30%
1 Year Change-22.97%
3 Year Change68.39%
5 Year Change-14.45%
Change since IPO-11.88%

Recent News & Updates

Shareholder Returns

532649IN PharmaceuticalsIN Market
7D-3.8%1.2%-1.1%
1Y-23.0%-13.0%0.5%

Return vs Industry: 532649 underperformed the Indian Pharmaceuticals industry which returned -13% over the past year.

Return vs Market: 532649 underperformed the Indian Market which returned 0.5% over the past year.

Price Volatility

Is 532649's price volatile compared to industry and market?
532649 volatility
532649 Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.8%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market3.7%

Stable Share Price: 532649 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 532649's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19951,669Amit Chadahhttps://www.neclife.com

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.

Nectar Lifesciences Fundamentals Summary

How do Nectar Lifesciences's earnings and revenue compare to its market cap?
532649 fundamental statistics
Market Cap₹5.11b
Earnings (TTM)₹271.52m
Revenue (TTM)₹16.87b

18.8x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
532649 income statement (TTM)
Revenue₹16.87b
Cost of Revenue₹12.28b
Gross Profit₹4.58b
Other Expenses₹4.31b
Earnings₹271.52m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.21
Gross Margin27.18%
Net Profit Margin1.61%
Debt/Equity Ratio79.0%

How did 532649 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 532649 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532649?

Other financial metrics that can be useful for relative valuation.

532649 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA8.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 532649's PE Ratio compare to its peers?

532649 PE Ratio vs Peers
The above table shows the PE ratio for 532649 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average29.2x
506414 Fermenta Biotech
38.5xn/a₹5.9b
506197 Bliss GVS Pharma
50xn/a₹8.3b
531633 Lincoln Pharmaceuticals
8.7xn/a₹5.8b
541400 ZIM Laboratories
19.4xn/a₹3.8b
532649 Nectar Lifesciences
18.8xn/a₹5.1b

Price-To-Earnings vs Peers: 532649 is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (29.2x).


Price to Earnings Ratio vs Industry

How does 532649's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 532649 is good value based on its Price-To-Earnings Ratio (18.8x) compared to the Indian Pharmaceuticals industry average (23.5x)


Price to Earnings Ratio vs Fair Ratio

What is 532649's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532649 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 532649's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 532649 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 532649 (₹22.8) is trading below our estimate of fair value (₹46.53)

Significantly Below Fair Value: 532649 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Nectar Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nectar Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Nectar Lifesciences is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Nectar Lifesciences competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Nectar Lifesciences performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-56.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 532649 has high quality earnings.

Growing Profit Margin: 532649 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 532649's earnings have declined by 56.2% per year over the past 5 years.

Accelerating Growth: 532649 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 532649 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.1%).


Return on Equity

High ROE: 532649's Return on Equity (2.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Nectar Lifesciences's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 532649's short term assets (₹13.5B) exceed its short term liabilities (₹10.0B).

Long Term Liabilities: 532649's short term assets (₹13.5B) exceed its long term liabilities (₹3.0B).


Debt to Equity History and Analysis

Debt Level: 532649's net debt to equity ratio (77.4%) is considered high.

Reducing Debt: 532649's debt to equity ratio has reduced from 88% to 79% over the past 5 years.

Debt Coverage: 532649's debt is not well covered by operating cash flow (11%).

Interest Coverage: 532649's interest payments on its debt are not well covered by EBIT (1.4x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Nectar Lifesciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 532649's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 532649's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 532649's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 532649's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 532649 is not paying a notable dividend for the Indian market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 532649 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Amit Chadah (52 yo)

1.92yrs

Tenure

Mr. Amit Chadah serves as the Chief Executive Officer of Nectar Lifesciences Limited since October 30, 2020. He was President of Business Development until October 30, 2020. He has joined the Nectar Lifesc...


Leadership Team

Experienced Management: 532649's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: 532649's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 4 shareholders own 57.04% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
44.35%
Sanjiv Goyal
99,468,000₹2.3b0%no data
11.59%
NSR Direct PE Mauritius, LLC
26,000,000₹592.8m0%no data
1.06%
Kotak Mahindra (UK) Ltd.
2,387,012₹54.4m0%0.72%
0.024%
Investor Education and Protection Fund (IEPF)
54,923₹1.3m0%no data

Company Information

Nectar Lifesciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Nectar Lifesciences Limited
  • Ticker: 532649
  • Exchange: BSE
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹5.113b
  • Shares outstanding: 224.26m
  • Website: https://www.neclife.com

Number of Employees


Location

  • Nectar Lifesciences Limited
  • SCO 38-39
  • Sector 9d
  • Chandigarh
  • Chandigarh
  • 160009
  • India


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532649BSE (Mumbai Stock Exchange)YesEquity SharesININRJul 2005
NECLIFENSEI (National Stock Exchange of India)YesEquity SharesININRJul 2005
NECLFBDL (Bourse de Luxembourg)GDR EACH REPR 1 ORD INR1 REG'S'LUUSDMar 2010

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.